142 related articles for article (PubMed ID: 32580276)
1. EP3 Is an Independent Prognostic Marker Only for Unifocal Breast Cancer Cases.
Zati Zehni A; Jeschke U; Hester A; Kolben T; Ditsch N; Jacob SN; Mumm JN; Heidegger HH; Mahner S; Vilsmaier T
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580276
[TBL] [Abstract][Full Text] [Related]
2. Hormone Receptor Expression in Multicentric/Multifocal versus Unifocal Breast Cancer: Especially the VDR Determines the Outcome Related to Focality.
Zati Zehni A; Jacob SN; Mumm JN; Heidegger HH; Ditsch N; Mahner S; Jeschke U; Vilsmaier T
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31731733
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Impact of Retinoid X Receptor and Thyroid Hormone Receptor alpha in Unifocal vs. Multifocal/Multicentric Breast Cancer.
Zehni AZ; Batz F; Vattai A; Kaltofen T; Schrader S; Jacob SN; Mumm JN; Heidegger HH; Ditsch N; Mahner S; Jeschke U; Vilsmaier T
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33478016
[TBL] [Abstract][Full Text] [Related]
4. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?
Weissenbacher TM; Zschage M; Janni W; Jeschke U; Dimpfl T; Mayr D; Rack B; Schindlbeck C; Friese K; Dian D
Breast Cancer Res Treat; 2010 Jul; 122(1):27-34. PubMed ID: 20454925
[TBL] [Abstract][Full Text] [Related]
5. EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.
Semmlinger A; von Schoenfeldt V; Wolf V; Meuter A; Kolben TM; Kolben T; Zeder-Goess C; Weis F; Gallwas J; Wuerstlein R; Hermelink K; Schmoeckel E; Harbeck N; Mayr D; Mahner S; Jeschke U; Ditsch N
BMC Cancer; 2018 Apr; 18(1):431. PubMed ID: 29661238
[TBL] [Abstract][Full Text] [Related]
6. Multicentric and multifocal versus unifocal breast cancer: differences in the expression of E-cadherin suggest differences in tumor biology.
Weissenbacher T; Hirte E; Kuhn C; Janni W; Mayr D; Karsten U; Rack B; Friese K; Jeschke U; Heublein S; Dian D; Ditsch N
BMC Cancer; 2013 Jul; 13():361. PubMed ID: 23890049
[TBL] [Abstract][Full Text] [Related]
7. Breast adipose tissue macrophages (BATMs) have a stronger correlation with breast cancer survival than breast tumor stroma macrophages (BTSMs).
Lin L; Kuhn C; Ditsch N; Kolben T; Czogalla B; Beyer S; Trillsch F; Schmoeckel E; Mayr D; Mahner S; Jeschke U; Hester A
Breast Cancer Res; 2021 Apr; 23(1):45. PubMed ID: 33849622
[TBL] [Abstract][Full Text] [Related]
8. The Prostaglandin EP3 Receptor Is an Independent Negative Prognostic Factor for Cervical Cancer Patients.
Heidegger H; Dietlmeier S; Ye Y; Kuhn C; Vattai A; Aberl C; Jeschke U; Mahner S; Kost B
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28753926
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
Aalders KC; Kuijer A; Straver ME; Slaets L; Litiere S; Viale G; Van't Veer LJ; Glas AM; Delorenzi M; van Dalen T; Tryfonidis K; Piccart MJ; Cardoso F; Rutgers EJ;
Eur J Cancer; 2017 Jul; 79():98-105. PubMed ID: 28477490
[TBL] [Abstract][Full Text] [Related]
10. EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer.
Czogalla B; Kuhn C; Heublein S; Schmöckel E; Mayr D; Kolben T; Trillsch F; Burges A; Mahner S; Jeschke U; Hester A
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2519-2527. PubMed ID: 31485769
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes.
Althobiti M; Muftah AA; Aleskandarany MA; Joseph C; Toss MS; Green A; Rakha E
Breast Cancer Res Treat; 2020 Aug; 182(3):581-589. PubMed ID: 32524353
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
13. The role of EP3-receptor expression in cervical dysplasia.
Hester A; Ritzer M; Kuhn C; Schmoeckel E; Mayr D; Kolben T; Dannecker C; Mahner S; Jeschke U; Kolben TM
J Cancer Res Clin Oncol; 2019 Feb; 145(2):313-319. PubMed ID: 30402741
[TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of RIP140 and ERβ expression in unifocal versus multifocal breast cancers: a preliminary report.
Müller K; Sixou S; Kuhn C; Jalaguier S; Mayr D; Ditsch N; Weissenbacher T; Harbeck N; Mahner S; Cavaillès V; Jeschke U
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669416
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
16. Ki-67 is a prognostic marker for hormone receptor positive tumors.
Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
[TBL] [Abstract][Full Text] [Related]
17. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
18. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
20. PI3K/AKT Signaling in Breast Cancer Molecular Subtyping and Lymph Node Involvement.
Bonin S; Pracella D; Barbazza R; Dotti I; Boffo S; Stanta G
Dis Markers; 2019; 2019():7832376. PubMed ID: 31781306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
